Sök artiklar i SveMed+

Observera: SveMed+ upphör att uppdateras!



Ropinirol i behandling af rastlöse ben
Engelsk titel: Ropinirole treatment of restless legs Läs online Författare: Kinge E ; Lossius MI ; Mowincel P Språk: Dan Antal referenser: 20 Dokumenttyp: Artikel UI-nummer: 05031337

Tidskrift

Ugeskrift for Laeger 2005;167(11)1284-6 ISSN 0041-5782 E-ISSN 1603-6824 KIBs bestånd av denna tidskrift Denna tidskrift är expertgranskad (Peer-Reviewed)

Sammanfattning

Introduction: Dopaminergic agents are the best studied and most successful agents for the treatment of restless legs syndrome (RLS). Recent studies suggest that the dopamine agonists should be the first line of therapy before levodopa. We present our clinical experience with the dopamine agonist ropinirole in the treatment of RLS. Materials and methods: We tested ropinirole in 18 patients with RLS in an open-label study. Average follow-up time was 8.2 months. The mean daily dose of ropinirole was 1.9 mg. Results: The patients showed a 47.7% improvement in RLS score based on a questionnaire from the International Restless Legs Study Group. Six patients (33.3%) reported side effects, most commonly nausea. Four patients (22.2%) discontinued ropinirole because of unacceptable side effects, lack of clinical effect and high cost. Discussion: Our study showed that patients' assessment of their symptoms after treatment with ropinirole improved but that side effects can be a problem.